» Articles » PMID: 25072257

The Prognostic Value and Therapeutic Target Role of Stathmin-1 in Urinary Bladder Cancer

Overview
Journal Br J Cancer
Specialty Oncology
Date 2014 Jul 30
PMID 25072257
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The oncoprotein-18/stathmin 1 (STMN1), involved in cell progression and migration, is associated with clinical outcome in breast cancer. Here we aim to investigate its clinical significance in urinary bladder cancer and its possibilities as a therapeutic target.

Methods: Immunohistochemical analyses of STMN1 protein expression were performed in three patient cohorts: cohort I (n=115 Ta, n=115 T1, n=112 T2-4 stages), cohort II, based on randomised controlled trials (n=239 T1-T4), and cohort III of primary tumour/matched metastasis (n=90 T1-T4). The effects of STMN1 on cell proliferation and migration were evaluated in the urinary bladder cancer cell line, T24, by inhibiting STMN1-cellular expression using siRNA.

Results: In cohort I, high STMN1 expression correlated to shorter disease-specific survival hazard ratio (HR)=2.04 (95% confidence interval (CI) 1.13-3.68; P=0.02), elevated p53- (P<0.001) and Ki67-protein levels (P<0.001). The survival result was validated in cohort II: HR=1.76 (95% CI 1.04-2.99; P=0.03). In the metastatic bladder cancer material, 70% of the patients were STMN1-positive in both the primary tumour and matched metastases. In vitro, the growth and migration of the T24 cells were significantly reduced (P<0.01, P<0.0001, respectively), when transfecting the cells with STMN1-siRNA.

Conclusions: STMN1 protein expression has prognostic significance but is primarily a potential treatment target in urinary bladder cancer.

Citing Articles

Stathmin 1 expression in neuroendocrine and proliferating prostate cancer.

Shi Y, Yeh Y, Cheng S, Gu X, Yang S, Li L Discov Oncol. 2025; 16(1):19.

PMID: 39776361 PMC: 11711591. DOI: 10.1007/s12672-025-01754-6.


Stathmin 1 Expression in Neuroendocrine and Proliferating Prostate Cancer.

Shi Y, Yeh Y, Cheng S, Gu X, Yang S, Li L Res Sq. 2024; .

PMID: 39711570 PMC: 11661371. DOI: 10.21203/rs.3.rs-5279702/v1.


A Novel Gene Expression Scoring System Predicts Recurrence in Non-Muscle-Invasive Bladder Cancer Patients.

Kayama E, Uemura M, Onagi A, Meguro S, Ogawa S, Yaginuma K Cancer Med. 2024; 13(22):e70349.

PMID: 39540204 PMC: 11561421. DOI: 10.1002/cam4.70349.


Potential Markers to Differentiate Uterine Leiomyosarcomas from Leiomyomas.

Guo J, Zheng J, Tong J Int J Med Sci. 2024; 21(7):1227-1240.

PMID: 38818470 PMC: 11134592. DOI: 10.7150/ijms.93464.


Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer.

Kerzeli I, Kostakis A, Turker P, Malmstrom P, Hemdan T, Mezheyeuski A BMC Cancer. 2023; 23(1):605.

PMID: 37391708 PMC: 10311740. DOI: 10.1186/s12885-023-11100-0.


References
1.
Baldassarre G, Belletti B, Nicoloso M, Schiappacassi M, Vecchione A, Spessotto P . p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell. 2005; 7(1):51-63. DOI: 10.1016/j.ccr.2004.11.025. View

2.
Yuan R, Jeng Y, Chen H, Lai P, Pan H, Hsieh F . Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol. 2006; 209(4):549-58. DOI: 10.1002/path.2011. View

3.
Saal L, Johansson P, Holm K, Gruvberger-Saal S, She Q, Maurer M . Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A. 2007; 104(18):7564-9. PMC: 1855070. DOI: 10.1073/pnas.0702507104. View

4.
Boyle P, Ferlay J . Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005; 16(3):481-8. DOI: 10.1093/annonc/mdi098. View

5.
Fristrup N, Ulhoi B, Birkenkamp-Demtroder K, Mansilla F, Sanchez-Carbayo M, Segersten U . Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. Am J Pathol. 2012; 180(5):1824-34. DOI: 10.1016/j.ajpath.2012.01.023. View